Noninferiority is (too) common in noninferiority trials

Journal of Clinical Epidemiology

Volumn 71, Issue , 2016, Pages 118-120

  Soonawala, Darius ^a   Dekkers, Olaf M ^a   Vandenbroucke, Jan P ^a   Egger, Matthias ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EXPERIMENTAL THERAPY; FUNDING; HUMAN; LETTER; META ANALYSIS (TOPIC); NONINFERIORITY; PRIORITY JOURNAL; PROBABILITY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL PARAMETERS; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; STATISTICS AND NUMERICAL DATA;

DRUG INDUSTRY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT AS TOPIC;

EID: 84983134256     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2015.11.009     Document Type: Letter

References (8)

1. [1] Flacco, M.E., Manzoli, L., Boccia, S., Capasso, L., Aleksovska, K., Rosso, A., et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol 68 (2015), 811–820.
2. [2] Soonawala, D., Middelburg, R.A., Egger, M., Vandenbroucke, J.P., Dekkers, O.M., Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials. Int J Epidemiol 39 (2010), 1567–1581.
3. [3] Bourgeois, F.T., Murthy, S., Mandl, K.D., Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 153 (2010), 158–166.
4. [4] Djulbegovic, B., Kumar, A., Soares, H.P., Hozo, I., Bepler, G., Clarke, M., et al. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med 168 (2008), 632–642.
5. [5] Djulbegovic, B., Kumar, A., Miladinovic, B., Reljic, T., Galeb, S., Mhaskar, A., et al. Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. PLoS One, 8, 2013, e58711.
6. [6] Dekkers, O.M., Cevallos, M., Bührer, J., Poncet, A., Ackermann Rau, S., Perneger, T.V., et al. Comparison of noninferiority margins reported in protocols and publications showed incomplete and inconsistent reporting. J Clin Epidemiol 68 (2014), 510–517.
7. [7] Dekkers, O.M., Soonawala, D., Vandenbroucke, J.P., Egger, M., Reporting of noninferiority trials was incomplete in trial registries. J Clin Epidemiol 64 (2011), 1034–1038.
8. [8] Bernabe, R.D.L.C., Wangge, G., Knol, M.J., Klungel, O.H., van Delden, J.J.M., de Boer, A., et al. Phase IV non-inferiority trials and additional claims of benefit. BMC Med Res Methodol, 13, 2013, 70.